Axecap Investments LLC Increases Stock Position in AbbVie Inc. $ABBV

Key Points

• Axecap Investments LLC boosted its AbbVie stake by 713.2% in Q4, acquiring 14,313 shares to hold 16,320 shares worth $3.73M, making AbbVie ~2.3% of its portfolio and its 12th-largest position.
• AbbVie beat Q4 estimates with $2.71 EPS and $16.62B in revenue (up 10% YoY), issued FY2026 EPS guidance of 14.370–14.570, and announced a $1.73 quarterly dividend (3.5% yield).
• The U.S. FDA issued a Complete Response Letter (CRL) for AbbVie’s trenibotulinumtoxinE due to manufacturing/process concerns, delaying potential commercialization and adding near-term regulatory uncertainty.

Axecap Investments LLC raised its holdings in AbbVie Inc. (NYSE:ABBV - Free Report) by 713.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 16,320 shares of the company's stock after purchasing an additional 14,313 shares during the quarter. AbbVie accounts for about 2.3% of Axecap Investments LLC's holdings, making the stock its 12th biggest position. Axecap Investments LLC's holdings in AbbVie were worth $3,729,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the company. Vanguard Group Inc. boosted its stake in shares of AbbVie by 1.7% during the 4th quarter. Vanguard Group Inc. now owns 180,779,699 shares of the company's stock worth $41,306,353,000 after acquiring an additional 3,032,438 shares in the last quarter. Legal & General Group Plc boosted its stake in shares of AbbVie by 4.3% during the 3rd quarter. Legal & General Group Plc now owns 12,004,084 shares of the company's stock worth $2,779,426,000 after acquiring an additional 493,420 shares in the last quarter. Wellington Management Group LLP boosted its stake in shares of AbbVie by 457.4% during the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company's stock worth $2,439,714,000 after acquiring an additional 8,646,424 shares in the last quarter. Amundi boosted its stake in shares of AbbVie by 15.6% during the 3rd quarter. Amundi now owns 10,508,317 shares of the company's stock worth $2,418,909,000 after acquiring an additional 1,414,621 shares in the last quarter. Finally, Ameriprise Financial Inc. boosted its stake in shares of AbbVie by 4.4% during the 3rd quarter. Ameriprise Financial Inc. now owns 9,675,877 shares of the company's stock worth $2,241,363,000 after acquiring an additional 408,426 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company's stock.

AbbVie Stock Down 1.1%

ABBV stock opened at $198.71 on Friday. The company has a market cap of $351.35 billion, a price-to-earnings ratio of 84.20, a PEG ratio of 0.72 and a beta of 0.38. The business has a fifty day simple moving average of $216.68 and a 200-day simple moving average of $222.33. AbbVie Inc. has a 52 week low of $176.57 and a 52 week high of $244.81.

AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping analysts' consensus estimates of $2.65 by $0.06. The business had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The business's revenue for the quarter was up 10.0% on a year-over-year basis. During the same period in the prior year, the firm posted $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, analysts expect that AbbVie Inc. will post 14.21 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.5%. The ex-dividend date is Wednesday, April 15th. AbbVie's dividend payout ratio is presently 293.22%.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie announced a major strategic investment: a $1.4 billion, AI-enabled manufacturing campus in Durham, NC that will create hundreds of permanent jobs and supports capacity for immunology, neuroscience and oncology medicines. This strengthens manufacturing footprint and long-term growth/production capacity. Article Title
• Positive Sentiment: Canaccord initiated coverage with a Buy and $262 price target (recent coverage highlighted AbbVie as a buy on pullback), providing bullish analyst support and upside from current levels. Analyst upgrades can buoy sentiment and attract inflows. Article Title
• Positive Sentiment: AbbVie struck an exclusive licensing deal with Haisco for development of pain medicines, expanding its pipeline and potential addressable market for pain therapeutics. Partnership deals can add optionality to future revenue. Article Title
• Neutral Sentiment: Wall Street previews and model-level estimates for Q1 (sales and key metric breakdowns) are circulating ahead of AbbVie’s April 29 earnings; these projections set expectations traders will use for the report. Meeting or beating estimates could stabilize the stock. Article Title
• Neutral Sentiment: Analysts and media continue to discuss AbbVie as a dividend-growth candidate and a long-term defensive healthcare holding; this maintains baseline investor interest but is unlikely to move shares sharply near-term. Article Title
• Negative Sentiment: The U.S. FDA issued a Complete Response Letter (CRL) for AbbVie’s trenibotulinumtoxinE (TrenibotE) — citing manufacturing/process issues rather than new clinical trials. AbbVie said it will respond and believes it can address comments, but the CRL delays potential commercialization and near-term revenue expectations for the neurotoxin program. Article Title
• Negative Sentiment: Multiple outlets report the CRL is tied to manufacturing concerns; while AbbVie noted no additional clinical studies were requested, regulatory manufacturing issues create uncertainty on timing and cost to obtain approval — a near-term headwind for sentiment. Article Title

Insiders Place Their Bets

In related news, SVP David Ryan Purdue sold 5,230 shares of the company's stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the sale, the senior vice president directly owned 2,654 shares of the company's stock, valued at approximately $619,868.24. This represents a 66.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Perry C. Siatis sold 22,381 shares of the firm's stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the transaction, the executive vice president directly owned 38,137 shares in the company, valued at $8,771,510. This represents a 36.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.06% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

ABBV has been the topic of several research analyst reports. Barclays initiated coverage on AbbVie in a research note on Thursday, February 19th. They set an "overweight" rating and a $275.00 price target on the stock. Canaccord Genuity Group assumed coverage on AbbVie in a research report on Monday, April 20th. They set a "buy" rating and a $262.00 price objective for the company. Wall Street Zen downgraded AbbVie from a "strong-buy" rating to a "buy" rating in a research report on Saturday, April 11th. Citigroup cut their price objective on AbbVie from $235.00 to $230.00 and set a "neutral" rating for the company in a research report on Tuesday, January 27th. Finally, Morgan Stanley lifted their price objective on AbbVie from $269.00 to $270.00 and gave the stock an "overweight" rating in a research report on Thursday, February 5th. Three analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the company's stock. According to MarketBeat.com, AbbVie has an average rating of "Moderate Buy" and an average price target of $253.19.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.